Keitaro Fukuda
Takeru Funakoshi- 1Department of Dermatology, University of Massachusetts Medical School, Worcester, MA, United States
- 2Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
A corrigendum on
In the published article, there was an error in the number of ongoing clinical trial for HER2-positive unresectable or metastatic EMPD “(UMIN-000006629)”. Instead of “(UMIN-000006629)”, it should be “(UMIN000021311)”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
The original article has been updated.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Keywords: metastatic extramammary Paget’s disease, HER2–PI3K/ERK signaling, lymphangiogenesis, CXCR4–stromal cell-derived factor-1 axis, CD163+M2 macrophage, receptor activator of nuclear factor kappa-B ligand–RANK signaling, mismatch-repair deficient, anti-PD-1 antibody
Citation: Fukuda K and Funakoshi T (2018) Corrigendum: Metastatic Extramammary Paget’s Disease: Pathogenesis and Novel Therapeutic Approach. Front. Oncol. 8:47. doi: 10.3389/fonc.2018.00047
Received: 19 February 2018; Accepted: 19 February 2018;
Published: 12 March 2018
Copyright: © 2018 Fukuda and Funakoshi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Approved by: Frontiers in Oncology Editorial Office, Frontiers, Switzerland
*Correspondence: Takeru Funakoshi, dGFrZXJ1ZkBhOC5rZWlvLmpw